Portal Diabetes Gets FDA Breakthrough for Pump, Starts Insulin Study
17 Feb 2026
National
Portal Diabetes, Inc. ("Portal") announced its receipt of the Breakthrough Device Designation by the Food and Drug Administration (FDA) for its implantable insulin pump system called "Portal Pump," and the start of a Phase 1 study on its proprietary temperature-stable insulin ("Portal Insulin").
The Westfield, Indiana company aims to deliver a functional cure to type 1 diabetes-- an implantable insulin pump leveraging the physiologic delivery of insulin to the abdomen, modern continuous glucose monitoring (CGM) technology, and stable, concentrated insulin to fully close the loop on insulin delivery for patients living with type 1 diabetes.
More Topics
After several years of tough conditions for buyers, there are reasons for optimism in 2026. Zillow’s outlook for 2026 calls for the housing market to settle into a healthier state, with buyers seeing a bit more breathing room.But the housing market isn’t moving in lockstep nationwide. An inventory crunch is...
Westfield, Indiana has quietly transformed from a community of fewer than 10,000 residents in the 1990s to the fastest-growing city in the state, now home to more than 50,000 people. The city ranks as the sixth-fastest-growing municipality in the country yet maintains a distinct identity. “Our motto in Westfield is...
Georgia is back on top — again. For the 12th consecutive year, the state has claimed the No. 1 overall ranking in Area Development’s annual Top States for Doing Business survey. While Georgia’s consistency speaks volumes, the real story in 2025 is just how competitive the field has become beneath...